A Cohort Study of Operationally Tolerant Allograft Recipients

Status Terminated

Clinical Trial Summary

Antirejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent their bodies from rejecting the new organ. Some organ transplant recipients can stop taking anti-rejection medicines without rejecting their transplanted organ (this is called 'tolerance'). The purpose of this study will collect samples and data from 'tolerant' liver or kidney transplant recipients in order to find out: The purpose of this study is to collect samples and data in order to find out: - How long liver or kidney transplant recipients can remain tolerant; - What happens in the tolerant recipient's body over time; and - If there are patterns in the body that are linked to tolerance.

Clinical Trial Description

This is a multi-center, prospective, observational study in which operationally tolerant recipients of liver or kidney allografts will be followed longitudinally, with annual collections of clinical data and biological samples. All participants will be followed for the duration of the study, regardless of changes in their tolerance status. Participants will be recruited by three main pathways: 1. Tolerant participants from current and past Immune Tolerance Network (ITN) trials, including those who have already completed trial participation and those who are anticipated to complete trial participation, 2. Tolerant participants referred by ITN affiliated investigators, academic and community transplant physicians and directly through outreach to transplant affinity groups such as the National Kidney Foundation (NKF), and 3. Tolerant participants from the general transplant community who are reachable through general contact channels such as the ITN website, word-of-mouth referrals from existing participants, and social media. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02743793
Study type	Observational
Source	National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status	Terminated
Phase
Start date	June 30, 2016
Completion date	March 24, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04087720` - Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant	Phase 4
Completed	`NCT03749356` - Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients	Phase 4
Recruiting	`NCT05811468` - Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients
Completed	`NCT03527238` - Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine	Phase 2
Completed	`NCT00498576` - Melatonin and Adiponectin in Hypertensive Kidney Transplant	N/A
Completed	`NCT00642655` - Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation	Phase 1/Phase 2
Completed	`NCT00374400` - The Paired Donation Consortium Paired Donation Program	N/A
Completed	`NCT01710033` - A Study Of CP-690,550 In Stable Kidney Transplant Patients	Phase 1
Completed	`NCT00205257` - Prediction of Acute Rejection in Renal Transplant	Phase 1
Completed	`NCT02711826` - Treg Therapy in Subclinical Inflammation in Kidney Transplantation	Phase 1/Phase 2
Withdrawn	`NCT03978494` - Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.	Phase 1
Completed	`NCT03837522` - Trial to Define the Benefits and Harms of Deceased Donor Kidney Procurement Biopsies	N/A
Not yet recruiting	`NCT06025240` - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Completed	`NCT05029310` - Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients	Phase 4
Completed	`NCT03644485` - Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients	Phase 4
Active, not recruiting	`NCT02409901` - Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients	N/A
Completed	`NCT01047410` - ACtive Care After Transplantation, the ACT Study	N/A
Completed	`NCT00940940` - Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation	Phase 4
Completed	`NCT00217126` - The Study of Long-term Deterioration of Kidney Transplants.	Phase 4
Completed	`NCT00270712` - A Study of Factors That Affect Long-Term Kidney Transplant Function

A Cohort Study of Operationally Tolerant Allograft Recipients — ALLTOL

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms